Cts Corp (CTS) · Oct 27, 2026 · Earnings
Beat — Adjusted EPS $0.77 vs ~$0.66 consensus; revenue $149.6M vs ~$146M
CTS earnings beat Q3 expectations, with 330-basis-point margin expansion and higher 2026 sales and adjusted EPS guidance.
CTS is a sensor, actuator and electronic-components maker trying to reduce its historical dependence on transportation by expanding industrial, medical, and aerospace & defense exposure. That diversification strategy was already underway, but this quarter shows it producing better growth and profitability: the company says diversified markets now represent 60% of sales, while the Millar acquisition adds medical and life-sciences sensing capabilities.
| Metric | Q3 2026 | Comparison / expectation |
|---|---|---|
| Revenue | $149.6M | $143.0M in Q3 2025; ~$146M consensus |
| Adjusted diluted EPS | $0.77 | $0.60 in Q3 2025; ~$0.66 consensus |
| Adjusted gross margin | 42.2% | 38.9% in Q3 2025 |
| Adjusted EBITDA margin | 24.7% | 23.8% in Q3 2025 |
| Operating cash flow | $43.5M | $29.0M in Q3 2025 |
| 2026 revenue guidance | $580M–$590M | Previously $565M–$585M |
| 2026 adjusted EPS guidance | $2.78–$2.88 | Previously $2.55–$2.70M |
The quarter was a genuine beat, not just a favorable presentation. Revenue exceeded the published consensus of roughly $146 million, while adjusted EPS of $0.77 was above the roughly $0.66 expectation. The beat was supported by operating improvement: adjusted gross margin expanded 330 basis points and adjusted EBITDA margin rose 90 basis points. CTS states, “Sales were $149.6million in the third quarter of 2026, up 5% year-over-year.”
The growth mix is moving in the direction CTS needs. Diversified end-market revenue grew 7% year over year, versus 2% growth in transportation, and represented 60% of quarterly sales. Industrial demand was solid, aerospace and defense bookings were particularly strong, and medical revenue grew 21% year over year, although medical bookings were softer and aerospace revenue remained uneven. CTS says, “Diversified end-market sales grew 7% and now represent 60% of total sales.” 〔0〕
The outlook upgrade is the clearest change to the standing story. Management raised both revenue and adjusted EPS guidance, taking the midpoint of the EPS range from $2.625 to $2.83—about an 8% increase—and the revenue midpoint from $575 million to $585 million. The upgrade includes the expected Millar contribution, but the quarter’s margin and cash-flow performance also give it operational support. CTS says, “CTS is increasing its previous guidance of 2026 sales from a range of $565-$585million to $580-$590million and adjusted diluted EPS from a range of $2.55-$2.70to $2.78-$2.88.”
The quality of the earnings still needs to be read carefully, but it does not erase the beat. GAAP earnings benefited from a $12.5 million insurance recovery, while adjusted EPS included a sizable $12.7 million discrete tax adjustment; those items are excluded or separately adjusted in CTS’s non-GAAP presentation. The more durable evidence is the improvement in adjusted gross margin, bookings, and cash generation: operating cash flow rose to $43.5 million and nine-month free cash flow reached $82.3 million. CTS says, “Operating cash flow was $43.5million, up $14.5million from $29.0million in the third quarter of 2025.”
Bottom line: This materially advances CTS’s diversification story: the company beat a reasonable Q3 benchmark, expanded margins, and raised full-year targets. The main caveat is that part of reported profitability was distorted by tax and insurance items, but the underlying operating and cash-flow trend still landed clearly better than expected.
Q4 earnings report, early February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!